Apart from making efforts to meet the requirements of India, the company is also trying its best to balance the needs of the rest of the world, he added.
Confirming the Drugs Controller General Of India (DCGI) approval, Serum Institute of India CEO Adar Poonawalla on Tuesday tweeted: '@SerumInstIndia's brand Covovax has completed bridging studies in India and has been granted Emergency Use Authorisation by DCGI for adults and for children above the age of 12. Younger age groups will follow shortly.'
In a series of tweets after the Drugs Controller General of India (DCGI) approved Oxford's vaccine Covishield and Bharat Biotech's Covaxin for restricted emergency use, Modi said it will make every Indian proud that both the vaccines are made in India.
SII's CEO Adar Poonawalla took to Twitter to announce the "philanthropic" gesture.
Covishield vaccine production won't be hit due to the fire, Serum Institute of India Chief Executive Officer Adar Poonawalla said. The Manjari facility is where the Covishield vaccine used in the nationwide inoculation drive against the pandemic is made.
Serum Institute has the capacity to make 250 million doses of Covishield monthly.
By January-February, it's expected to have at least 100 million doses for the Indian government, reports Sohini Das.
The Pune-based vaccine major has entered into a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine.
The approval by the Drugs Controller General of India (DCGI) was given on the basis of recommendations submitted by a COVID-19 subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).
